About ProtoKinetix (OTCMKTS:PKTX)
ProtoKinetix, Incorporated is a research and development-stage bio-technology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). AFGP is a compound produced by fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures. HealthCare Applications of AAGP fall into various categories, such as harvesting, storage and transplanting cells, tissues and organs, and treatments for conditions and diseases caused by stress factors, including ultraviolet (UV) radiation, oxidation and inflammation. As of December 31, 2016, the Company had no revenue.
Industry, Sector and Symbol
Trailing P/E Ratio-5.3
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-209.79%
Return on Assets-205.28%
ProtoKinetix (OTCMKTS:PKTX) Frequently Asked Questions
What is ProtoKinetix's stock symbol?
ProtoKinetix trades on the OTCMKTS under the ticker symbol "PKTX."
Who are some of ProtoKinetix's key competitors?
Some companies that are related to ProtoKinetix include Innovus Pharmaceuticals (INNV), Regenerx Biopharmaceuticals (RGRX), HealthWarehouse.com (HEWA), AIT Therapeutics (AITB), Noble Roman's (NROM), Resaas Services (RSASF), Black Ridge Oil & Gas (ANFC), Destiny Media Technologies (DSNY), Sierra Monitor (SRMC), Pacific Drilling (PACDQ), Vernalis (VNLPY), Atna Resources (ATNAQ), Acura Pharmaceuticals (ACUR), OMNI-LITE INDS CAN (OLNCF), Premier (PRHL), Deep Down (DPDW), B456 Systems (AONEQ) and Trxade Group (TRXD).
Who are ProtoKinetix's key executives?
ProtoKinetix's management team includes the folowing people:
- Clarence E. Smith, President, Chief Executive Officer, Director (Age 50)
- Michael Richard Guzzetta, Chief Financial Officer (Age 60)
- Edward P. McDonough, Director (Age 63)
Has ProtoKinetix been receiving favorable news coverage?
Headlines about PKTX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ProtoKinetix earned a coverage optimism score of 0.17 on Accern's scale. They also gave news coverage about the company an impact score of 46.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are ProtoKinetix's major shareholders?
ProtoKinetix's stock is owned by a number of of institutional and retail investors. Top institutional investors include
SMITH CLARENCE EDWARD
YOUNG LACHLAN GRANT
YOUNG LACHLAN GRANT
(10.40%). Company insiders that own ProtoKinetix stock include Clarence Edward Smith and Susan Marie Woodward. View Institutional Ownership Trends for ProtoKinetix.
How do I buy shares of ProtoKinetix?
Shares of PKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProtoKinetix's stock price today?
One share of PKTX stock can currently be purchased for approximately $0.05.
How big of a company is ProtoKinetix?
ProtoKinetix has a market capitalization of $14.27 million.
How can I contact ProtoKinetix?
ProtoKinetix's mailing address is 412 Mulberry St, MARIETTA, OH 45750-2016, United States. The company can be reached via phone at +1-304-2995070.
MarketBeat Community Rating for ProtoKinetix (PKTX)MarketBeat's community ratings are surveys of what our community members think about ProtoKinetix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
ProtoKinetix (OTCMKTS:PKTX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
ProtoKinetix (OTCMKTS:PKTX) Earnings History and Estimates Chart
ProtoKinetix (OTCMKTS PKTX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
ProtoKinetix (OTCMKTS:PKTX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ProtoKinetix (OTCMKTS:PKTX)
No dividend announcements for this company have been tracked by MarketBeat.com
ProtoKinetix (OTCMKTS PKTX) Insider Trading and Institutional Ownership History
ProtoKinetix (OTCMKTS PKTX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/12/2018||Clarence Edward Smith||CEO||Buy||2,359,240||$0.05||$117,962.00|| |
|2/6/2017||Clarence Edward Smith||CEO||Buy||750,000||$0.04||$30,000.00||53,820,500|| |
|2/6/2017||Susan Marie Woodward||CFO||Buy||250,000||$0.04||$10,000.00||250,000|| |
|12/20/2016||Clarence Edward Smith||CEO||Buy||4,000,000||$0.04||$160,000.00||53,070,500|| |
|11/4/2016||Clarence Edward Smith||CEO||Buy||1,250,000||$0.04||$50,000.00||45,570,500|| |
|9/23/2016||Clarence Edward Smith||CEO||Buy||321,263||$0.06||$19,275.78||43,820,500|| |
|9/15/2016||Clarence Edward Smith||CEO||Buy||1,595,553||$0.04||$63,822.12||43,820,500|| |
|8/25/2016||Clarence Edward Smith||CEO||Buy||90,753||$0.05||$4,537.65||41,320,500|| |
|7/7/2016||Clarence Edward Smith||CEO||Buy||90,000||$0.06||$5,400.00|| |
|7/1/2016||Clarence Edward Smith||CEO||Buy||1,900,000||$0.04||$76,000.00|| |
|6/24/2016||Clarence Edward Smith||CEO||Buy||175,000||$0.06||$10,500.00||43,092,157|| |
|6/16/2016||Clarence Edward Smith||CEO||Buy||780,000||$0.04||$31,200.00||42,152,157|| |
|5/25/2016||Clarence Edward Smith||CEO||Buy||100,000||$0.06||$6,000.00||42,072,157|| |
|5/18/2016||Clarence Edward Smith||CEO||Buy||145,000||$0.07||$10,150.00||41,919,157|| |
|5/11/2016||Clarence Edward Smith||CEO||Buy||173,380||$0.06||$10,402.80||41,777,157|| |
|5/3/2016||Clarence Edward Smith||CEO||Buy||416,000||$0.06||$24,960.00||41,365,677|| |
|4/28/2016||Clarence Edward Smith||CEO||Buy||214,646||$0.05||$10,732.30||40,109,631|| |
|4/25/2016||Clarence Edward Smith||CEO||Buy||402,631||$0.04||$16,105.24||40,714,781|| |
|3/19/2015||Clarence Edward Smith||CEO||Buy||1,500,000||$0.05||$75,000.00|| |
ProtoKinetix (OTCMKTS PKTX) News Headlines
ProtoKinetix (OTCMKTS:PKTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ProtoKinetix (OTCMKTS PKTX) Stock Chart for Thursday, March, 22, 2018